Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Gemcitabine and Cisplatin in High-Risk UTUC
NCT06927128Phase 2Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- May 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and cisplatin in upper tract urothelial carcinoma (UTUC), sponsored by Changhai Hospital. Primary endpoint: Pathological Response Rate. Planned start May 2025; status: not yet recruiting.
02
Drugs
gemcitabinecisplatin
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT06927128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06927128.